SMN2 and proximal spinal muscular atrophy: Interestingly, histone deacetylase (HDAC) inhibitors, such as valproic acid and Trichostatin A, have been tested for the treatment of SMA, with the goal of increasing SMN2 transcription levels by modulating promoter accessibility (Avila et al., 2007; Narver et al., 2008).